WO2002013838A1 - Seal-oil-based pharmaceutical, cosmetic, dermo-cosmetic, hygiene, alimentary and para-alimentary (food-supplements) products; their methods of preparation; their uses as preventive and/or as therapeutic agents - Google Patents
Seal-oil-based pharmaceutical, cosmetic, dermo-cosmetic, hygiene, alimentary and para-alimentary (food-supplements) products; their methods of preparation; their uses as preventive and/or as therapeutic agents Download PDFInfo
- Publication number
- WO2002013838A1 WO2002013838A1 PCT/PT2001/000020 PT0100020W WO0213838A1 WO 2002013838 A1 WO2002013838 A1 WO 2002013838A1 PT 0100020 W PT0100020 W PT 0100020W WO 0213838 A1 WO0213838 A1 WO 0213838A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- seal
- products
- vegetable
- cosmetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Definitions
- This current invention is related to Compositions (Compounds ' , or Products) for topical and non-topical use, characteristically containing seal-oil and/or the respective essential fatty acids (EFA's) of the Omega- 3 ( ⁇ -3) series and/or physiologically-and-therapeuticalfy-acceptable salts thereof; and/or any seal-oil-de- rived phospholipids and/ /or the respective derivatives; and/or other components of seal-oil and the derivatives thereof; these Compositions (Compounds) can be enriched with Liposomes or Phitosomes, and / or other ctive Ingredients (reinforcing the effects elicited by the Seal-Oil ⁇ -3EFA's or by other Components typical of Seal-oil; and/or compensating simultaneously existing cellular deficiencies); the usages of said Compositions or Products, as well as to their methods or processes of preparation.
- Compositions Compounds ' , or Products
- this invention is also related to the use, either as preventive or as therapeutic agents, of said Compositions (Compounds, or Products) ' , which make use of ⁇ -3EFA's and/or any seal-oil-derived phospholipids and/pr the respective derivatives; and/or other components typical of seal-oil) or their respective derivatives, which will be found useful and adequate in the perspective outlined here.
- Compositions Compounds, or Products
- compositions can be used either isolated or in different combinations.
- the ⁇ -3EFA's and/or their acceptable salts, the phospholipids and/or their acceptable derivatives, and/or other seal-oil components and/or their acceptable derivatives can be obtained by extraction from seal-oil, but they can also be extracted from other natural sources or be obtained through chemical or bio-technological or bio-engineering synthesis.
- Cosmetic products laboratories, enterprises and firms are particularly interested in formulating treatinent cosmetics and/of treatments endowed with beneficial effects upon the skin, the mucosal membranes and their associated, allied structures (phanerae) - such as hair and nails. It is widely known that animal-derived prq- ducts exert beneficial effects upon the skm s the mucosal membranes and the associated, allied structures (phanerae) and this has rendered the incorporation of substances of this type in cosmetics and personal-care products, as well as in dermo-cosmetics.and pharmaceutical products, including those with a decidedly therapeutic vocation.
- ⁇ -3EFA's (aiid/or their physiologically acceptable Salts) are widely distributed in the vegetable and animal kingdoms, where they play ubiquitous, frequent and relevant roles, namely in the realms of cellular functions and the functional regulation of cellular and intra-cellular membranes.
- Phospholipids also are essential constituents of the cell structures (whether these are part of the different membranes or not) and they can be (or become) "denatured” ("denatured” ?) by the inclusion in their own molecular structure of elements having a structure very close (or similar) to that of the normal physiologic elements normally found in said cell structures but differing from them th ⁇ ough small changes as those, for instance, induced by the manipulations and treatments usually imposed by the western civilisation industries to industrially extracted or treated to foods and/or their ingredients - such as the rotation of asymmetric carbon atoms, and/or other subtle and little apparent changes which tender physiologically determinant molecules incapable of fully carrying out their physiological roles.
- seal oil may have important physiologic fimctions and be important to counter of substances which are the object of similar (or different) impacts (such as those inducing the appearance of isorhers and other altered rn ⁇ lecules acting as antagonists - either isosteric or allosteric) making their physiological functions impossible.
- seal oil or of it!s elements (and/or of their respective derivatives) by oral or parenteral route, under formulations such as food supplements or pharmaceutical preparations has been shown to be useful in the prevention or the reversion of dysfunctional and/or involutive (ageing) processes inciding in the cellular (and intra-cellular) membranes, since th ⁇ y carry out functions which are of great importance for the biochemical regulations in the cell-membrane, intra-cellular and inter-cellular spaces.
- seal-oil (as well as its ⁇ -3EFA's and/or their acceptable salts, its phospholipids and / or their acceptable derivatives, and/ /or other seal-oil components and/or their acceptable derivatives are very well absorbed by the topical route when presented in ah adequate formulation, such absotption being .
- seal-oil (or, rather, Seal-Oils, since different compositions are known to exist for different species or even for different strains of seals), as well as its ⁇ -3EFA's and/or their acceptable salts, its phospholipids and/or their acceptable derivatives ?
- seal-oil components and/or their acceptable derivatives possess properties and characteristics which are most interesting and useful to be exploited, once adequately formulated, in the domains of cosmetic, dermo-cosmetic and pharmaceutical prevention and therapy, as well as in Alimentary, Para-Alimentary.and Hygiene (Consumer) Products Said use and exploitation is based on the fact that the referred Compositions (or Compounds) have properties which induce humidifying, anti-dehydration, emollient, elastifying, restorative, and allied or similar effects.
- the concentrations of seal-oil, its ⁇ -3EFA*s and/or their acceptable salts, its phospholipids and/or their acceptable derivatives, and/ /or other seal-oil components and or their acceptable derivatives, in this current invention may vary within very ample limits, according to the intended aims and goals and the fonnulation : for example, th ⁇ y can be used within the interval comprised between 0,01 % and 99,50 % weight/weight, preferably between 0,1 % and 40 % weight/weight.
- Seal oil has an extremely low systemic toxicity and a topical toxicity close to nihil, according to tests carried out in animals. Besides, it is important to state that seal oil has been shown to contain the ⁇ -3EFA's in proportions which match those of the human body - a characteristic which immediately makes seal-oil a preferential source of said ⁇ -3EFA's for human use.
- Olive Oil is, of all those which are known, the natural fat most suited for human consumption in what concerns the preparation of food at high temperatu-re. In fact, not only have scientific, modern, clinical studies demonstrated that Olive Oil lowers total cholesterolemia and raises HDL-cholesterol ⁇ the "good- colesterol"), but also Olive Oil has been shown to be the only edible fat which will go through heating to 200 0 C without significant generation of products harming health.
- Olive Oil is insufficiently rich in those AGE (or EFA's) - which the human organism is unable to synthesize Out of other fats (this being the reason for EFA's really being ESSENTTAI for human heath ..,). It would therefore be ideal if Olive Oil was endowed with said EFA's in proportions covering the daily needs of each Consumer. This being so, by adding hatural oils (or fats), rich in EFA's (or even the adding purified EFA's) to Olive Oil, it will be possible to obtain mixtures which are non-existing in Nature but which shall have great higher dietetic value p guarantee feedi g habits ensuring good, equilibrated health to those who adopt them.
- the ingestion of said fats enriched with the EFA's needed to avoid all and every state of carency (in EFA's) of the organism shall be capable of doing tj p correcgao and, a fortiori, the prevention of many illnesses, among which the following deserve being mentioned : arteriosclerosis (and platelet hiperag- gregability and hiper-adhesiveness, hiper-coagulability and low blood thrombo-lyic activity); doencas de tipo rheumath ⁇ id; states of excessive dryness of the skin and/or the mucosai membranes, and skin diseases triggered or aggravated by said states of care ⁇ cy; illnesses (of the intestines and other organs, as it happens in the eyes and in feminine genital organs) involving mucosal inflammation and immunitary; neurologic and psychologic dysfunctional processes.
- arteriosclerosis and platelet hiperag- gregability and hiper-adhesiveness, hiper-coagulability and
- fish oils mostly and preferably ; from fat fish (salmon, Sardine, halibut, shark, thunafish, etc, etc.);
- alimentary products shall be prepared (through mixing Olive Oil with with other fats) capable of supplying to the human body healthier alimentary fats (exempt of toxicity), and being complete (through containing the Essential Fatty Acids or EFA's, whose want trigger states of carency).
- Said enriched fats are therefore preventive of phisiopatologically seroius carencies, which induce the loss of health and of immunity against illnesses) and superior to those usually proposed for sale to the public, avoiding carencies of serious consequences for the maintenance of a healthy state and of the capacity tp defend himself, (directly ou indirectly) of multiple diseases,.
- EFA's Essential Fatty Acid
- n-6 or ⁇ mega-6
- n-3 or ⁇ mega-3
- cis-linoleic and alfe-linplenic acids are devoid of activity (except that of serving as energy substrates - being "burnt" i cellular metabolism to generate energy for the cell) while they have not been specifically bio-transformed in the human body, as shown hereafter 1 :
- D6D delta-6-desaturase
- AGL alpha-1-linolenic acid
- DGLA dihomo*gamma-hnplenic acid
- the EFA's of these two series are not interchangeable in animals. It is. orthy noting the low activity of delta-5-desaturase no Man and the guinea-pig, while it is high in mice and rats.
- EFA's are important for two foundamental reasons: (a) they are constituents of all membranes in all tissues of the body, playing a role which is vital for determining the characteristics and the biological capacities of their respective membranes - it is therefore logic that EFA's deficiencies trigger great dysfunctions in all body tissues; and (b) EFA's are the precursors of a group of highly reactjve and very efemerous substances - prostaglandins (PG's), leuco-trienes ⁇ LT's) and other related molecules, such as fhromboxaiies (TX's), which intervene in an infinity of cell and organ processes.
- PG's prostaglandins
- TX's fhromboxaiies
- PG's, LT's and related molecules with biological importance have been identified, acting ai local messangers in the regulation of the activity of different tissues and organs where they are produced.
- Arachidonic acid (AA) has very different and varied effects through the products it generates.
- PGI2 prostaciclin
- TXA2 thrpmboxane A2
- PGF2 thrpmboxane A2
- TX's thromboxahes
- AAS a OH-acid derived I from DGLA) LT's PG's an TXA2
- NSAI's no ⁇ -steroidal anti-inflammatorieS
- AAS acetyl-sallicilic acid, or aspirin
- delta-5-d ⁇ saturase is very little active in the human species, diet may have an important impact in the (quantitative and qualitative) regulation of the equilibrium of the series of PG's referred above.
- ljnoleic acid whichh originates DGLA
- AA is found nainly in meats and seafood (shrimos being particularly rich in AA).
- Kidney hypertrophy and haemorrhages, with rehal insufficiency 7. Kidney hypertrophy and haemorrhages, with rehal insufficiency.
- Alcohol (ethyl) inhibits the activity of delta-6-desaturase (D6D).
- Gluco-corticoids (high in long-lasting stress) inhibit the activity of D6D.
- Seal Oil is particularly endowed with (Omega-3) Essential Fatty Acids (Omegar3 EFA's or simply ⁇ -3EFA 's) necessary (and, above all, well suited) to the human organism, particularly because it contains all ⁇ -3 EFA's which are known to exist in (and are needed by) the human species and because those same ⁇ -3 EFA 's are found in the same proportions in the tissues of the human body.
- (Omega-3) Essential Fatty Acids (Omegar3 EFA's or simply ⁇ -3EFA 's) necessary (and, above all, well suited) to the human organism, particularly because it contains all ⁇ -3 EFA's which are known to exist in (and are needed by) the human species and because those same ⁇ -3 EFA 's are found in the same proportions in the tissues of the human body.
- Such deficiency states normally involve serious cellular dysfunctions, affecting different organs, not only because said EFA intervene directly in metabolic chains as substracts or regulators (an example of that being the metabolism of prostaglandins)., but also because, inadequate FA overloads alter significantly the permeability and the selectivity of different cellular membranes, thus excessively impeding and/or facilitating the passage of substances across cell membranes.
- This causes ill functioning (with clinical symptoms ranging from light to intense) related with deficiency (relative or not) and/or overload (relative or not) of metabolites and products (which may be .essential as, for example, water) states which are detrimental for the good ftinotioning of cells.
- O arachidonic acid is a n-6 series EF A biochemically Junior (essential) in the human body economy. Its concentration serum phospholipids and in thp lipids of different organs is changed by n-3 EFA's. Administered $ an isolated preparation, EPA and DHA slightly and similarly dpcrea-sed the levels of AA. But their own concentrations increased sharply. EPA lpwered DHA circa 15 % Jjut raised DPA more than 100 %. On the contrary, DHA lowered DPA concentration by 1/3 while EPA levels increased :
- DHA may be the object of a shortening of its chain so as to generate EPA, hile EPA can be easily converted to DPA It bepame evident, througli tiie studies carried out : contraaily to what is usual for products alien to the human body (xenobi ⁇ tics, such as, for example, aspirine), linear dose-effect curves of correspondence are not easily established.
- DPA is a usual and phisiologial comonent of human blood (a biological, therefore) and, jn circulating phospholipids reaches in general concentrations circa half of those found for EPA, which for a long time was thought to be the active component in the cardio-vascular system essential to the eskimo dipt. 2
- Such newly formed stereo-isomers are rqetabolically antagonists,to (against) the physiological metabolic use of the still existing ⁇ -3EFA's because they act as (isosteric and/or allosteric) bi ⁇ -chemical competing antagonists -which extraordinarily aggrav te the scarce- ⁇ ntake-of- ⁇ -3EFA's-deficiencies - extremely frequent today because almost all alimentary vegetable fats the public consmner (today) can buy are precisely extracted under high heat (160 to 300°C) and high pressure of circa 2,5 to 3 atmospheres (both resulting in much higher yields of those fats).
- PG are recognised participants in the fine control of inflammatory prpcesses, as "second messengers".
- second messengers the skin of persons deficient in EFA is particularly prone to inflammatory, scaling, or pther types of processes - which can manifest themselves as important components of clinical entities, such as eczema, dermatitis (urticarious, erithematous, psoriatic), etc., etc..
- seal-oil was (pharmacologically) synergised and enriched by thp use of Liposomes (or Phito- somes) and of Active Ingredients which reinfo ⁇ ce the effects of characteristic seal-oil ⁇ -3EFA's - revealed themselves to be particularly active in the clinical essays we have carried out to treat problems - de ⁇ natologic and of those afflicting other fields (gynecologic, ocular, ENT ? respiratory, digestive, urinary) - related to Skin ahd JVIucosal problems linked to clinically detectable ⁇ -3EFA's deficiencies.
- Seal Oil is endowed with a specific EFA - DRA, or Docosa-pentaenoic acid (22:5, n-3) which has been shown to induce (a) inhibition of vascular smooth muscle cells; and (b) the migration of endothelial cells and the endothelial repair of blood vessels, an effect confirming its usefulness in thp prevention of vascular diseases, namely, that of arteriosclerosis; besides, it has been shown that DPA is far more active that other EFA's; and that other EFA's, specifically those which exist in fish-oils, such as EPA (eicosa-pehtaenoic acid [20:5,n-3]) and DHA (docosa-hexae ⁇ oic acid [22:6,n-3]), recognized as useful in the fight againstvascular diseases, act through their transformation into DPA, which has been shown to be 10 times more active than EPA in what concerns the migration of endothelial cells.
- EFA eicosa-pehta
- Seal Oil and its derivatives namely DPA and/or at least those containing DPA, such a phPspholipids andtriglyce- tides
- Said Products shall contain the Active Ingredients in varying quantities and proportions (without necessarily going beyond, in Cosmetic and Dermo-Cosmetic Products, the concentrations of 30 % in terms of weight weight or weight /volume).
- a certain number of these Ingredients may not be present in some Products (and in the respective Formulations) :
- Excipients among which the following may be the chosen ones : Water (distilled or demineralized), which may amount to 40 to 75 % (W: W or weight : weight) of the final product; Glycerol, which will amount to 2,5 a 10 % (W : W) of the final product; Emulgin (product n° 7450 in Merck Index), which will amount to 1,5 a 5 % (W : W) of the final product; Myristol (product n° 6184 in Merck Index), which will amount to 2,5 a 10 % (W : W) of the final product; Isoprop'ylpalmitate, which will amount to 2,5 a 10 % (W : W) of the final product; Alcohol, which will amount to 1,5 a 5 % (W : W) of the final product;
- Vegetablee Oils (namelly those of evening primrose or field borage, of grape seeds, etc.) rich in ⁇ - 3EFA's - or the respective ⁇ -3EFAY, they will represent 7,5 to 15 % (W: W) of the final product;
- De-acylated glycerophospholipids glycero-phosphoryl-choline; glycero-phosphoryl-inositol; glycero- phosphoryl-serine; glycero-phosphoryl-ethanolamine; etc.
- De-acylated glycerophospholipids glycero-phosphoryl-choline; glycero-phosphoryl-inositol; glycero- phosphoryl-serine; glycero-phosphoryl-ethanolamine; etc.
- their respective physiologically accp- ptable salts ih concentrations ranging from 0,1 % to 10 % (W:W);
- Silicotte(s) (cyclomethicone, dimethicone coliopol, cyclomethicpne, etc.).
- Ubiquinone or ubidecarenone or Co-enzyme Q-10 - a natural product acting as a potent and physiologic anti-oxidant which our experiments have revealed is capable of completely reverting inflammatory skin processes due to physical, chemical agents (burns, etc.) or biologipal agents.
- Liposomes or Phitosomes made so as to contain and/or help deposit said ⁇ -3EFA's and or Q-i0 and/or Ingredients such as those in this list on the surface of cell membranes of those cell we aim at enriching With these Active Ingredients.
- Silver Salts (tliose metabolically more active and directed at cell fractions more specifically mvolved ih cellular respiration and in energy production and control) -because we confirmed that silver is one oligo- element capable of augmenting the efficacy of Q-10; said salts are, for examplpj, orotate, gluponate, picoli- nate, and all those capable of easy penetration into cell structures - butyrate and its immediate derivatives and other salts of amino or fatty acids of low molecular weight - can be used to alter energy metabolism at cellular mitochondrial and nuclear level;
- vitamina Bl cocarboxylase, if possible under stabilised form
- a d/ r ATP Ad/ r ATP (Adenosine-tri-phosphate - dissodic or other) under a form capable of promoting and activating energy production and/or liberation even in visibly deficient cells o_r those under aggression or intoxication decreasing such processes significantly;
- Anti-oxidants - such as vit.
- poliphehols including picnogenot
- catechines and their elements and polimers;
- coral- calcium CC, extracted in QMnawa and Tokunoshimo Islands, in Japan, and marketed, outside Japan, by the Swedish firm PMG - Preventive lytedical Group
- other oligo-elements including chromium and
- Chelanting agents and ion-exchange substances as, for example, calcium-EDTA); .
- Enzymes specially enzymes capable of digesting and mobilising blood components (a good example is hirudin) or components of connective pr elastic tissue (for example, cbllagenase and elastase);
- Preparation Mix the indicated ingredients at 40 °C temperature, under stirring and allow cooling.
- phase (I) Mix the components of phase (I) with water and heat up to 54 °C;
- phase (ll) Mix the components of phase (ll) with water and heat up to 54 °C;
- Example 3 DERMO-COSME ⁇ C HYDRATING 1 LOTION (I) (P/P) a Seal-oil 10,0 % ou Seal-oil (5,0 %) + Fish-oil (3,0 %) + ⁇ leo vegetable (2,0 %) 10.0 % b methyl p-oxybenzoate 00,7% c propyl p-oxybenzoate 00,3 % d Glycerylphosphorylchpline 35,0 % e Demineralized Watef (diluting) q.s, up to 100,0 %
- Dissolve Seal-oil (or a mixture of oils indicated above) and os conservantes in water tepid de-ionized; Add a Glycerylphosphorylcholine, stirring slowly.
- Example 4 LQTIONHYDRATINGDERMO-COSMETIC (H) (p/p) a Seal-oil 07,0 % or Seal-oil (5,0 %) + Fish-oil (3,0 %) + Vegetable Oil (2,0 %) 07.0 % b Glyceryl Stearate 00,5 % c Isocethyl Stearate 10,0 % d Lanolinic Ether PPG-10 00,3 % e Lanolinic Alcohol 00,7 %, f Acido oleic 02,0 % g Triethanolamine 01,3 % h Carbomer 941 00,1 % i Glycerol 04,0 % j Conservative Agent(s) 00,4 % k 5 % Solution of carrot extensin 05,0 % 1 Polipeptides of 5 % extensina hydrolisate ("Vegagen" Centerchem 5 ) 05,0 % e Demineralized Water (diluting) q
- Dissolve Seal-oil or the mixture of oils indicated above
- the conservative agents in tepid de-ionized water; Add the ofhpr elements, under stirring.
- Example 5 MAKE-UP CREAM (A) : ( ip) ⁇ Seal-oil 10,0 % or Seal-oil (5,0 %) + Fish-oil (3,0 %) + Vegetable OIL (2,0 %) 10.0 % b Bees Wax 03,0 % c Polyglyceryl-4-oleate 02,0 % d Silicones (ciclomethicone and dimethicone coliopol) 08,0 % e Silicone (cyclomethipone) 08,0 % f Glycerylphosphorylethanolamine 01,0 % g !pigments 15,0 %
- Example 6 CREAM of MAKE-UP (B) : (I) (P/P) a . Seal-oil 10,0 % or Seal-oil (5,0 %) + Fi?h-oil (3,0 %) + Olep vegetable (2,0 %) 1Q.0 % b Bees Wax 03,0 % c Polyglyceryl-4-oleate 02,0 % d Silicones (cyclomethicone and coliopol of Dimethicone) 08,0 % e Silicone (cyclomethicone) 08,0 % f Glycerylphosphorylethanolairiine 01,0 % g Pigments 15,0 %
- Example 7 HYDRATING CREAM (I): ( ip) a Seal-oil 10,0 % or Seal-Oil (5,0 %) + Fish-oil (3,0 %) + Olep vegetable (2,0 %) 10.0 %
- Example 8 MAKE-UP C_REAM (C) : (p/p) a Seal-oil (5%) or or Seal-oil (2,5 %) + Fish-oil (1,5 %) + Vegetable Oil (1,0 %) 05,0 % b Octildodecyl-stearyl Stearate 04,0 % c Is ⁇ cetyl Stearate 01,0 % d Propilene-glycol 03,0 % e Iron Oxydp 02,0 % f Titanium Dioxyde 08,0 % g
- Tensioactive Agents 7 (lecithin, polisorbate 20, sorbitane laurate) 01,0 % h Trietiianolamine 01,5 % i Conservative agents 00,6 % j Aglutinating and Thickening Agents 01,8 %
- Dissolve Seal-oil or the mixture of oils indicated above
- the conservative agdnts in tepid de- ionized water Add the other elements, under stirring.
- Example 11 MASCARA GEL : ( pip) a Seal-oil 10,0 % or Seal-oil (5,0 %) + Fish-oil (3,0 %) + Vegetable Oils (2,0 %) 10.0 % b 1,2-propanodiol 02,0 % c , Glyceryiphosphorylcholine (at 85 ° in Demineralized Water) 00,2 % d Carbomer 940 00,2 % e Triethanolamine 00,2 % f 95 "Ethyl Alcohol 10,0% g PVP (poliviny ⁇ pyrrolidone K 30) 01,0 % h Conservative agents q.s. i Pigments q.s. e Deminetfalked Water (diluting) q.s. up to 100,0 %
- Example 12 CAPILLARY TONIC in CREAM FOR WASHING : (pip) a Seal-oil 05,0 % or Seal-oil (2,5 %) + Fish-ofl (1,5 %) + Vegetable Oils (1,0 %) 05.Q % b Stearalconium Cloride 02,0 % c "Ceteareth 20" 02,0 % d Citric Acid 00,3 % e Dimethicone 00,2 % f Gum of antano 00,5 % g Cethyl Alcohol 01,0 % h Stearilic Alcohol 00,5 % i 1 % Solutio of maize extensine 00,2 % j Demineralized Water (diluting) q.s. up to 100,0 %
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001282730A AU2001282730A1 (en) | 2000-08-16 | 2001-08-16 | Seal-oil-based pharmaceutical, cosmetic, dermo-cosmetic, hygiene, alimentary andpara-alimentary (food-supplements) products; their methods of preparation; thei r uses as preventive and/or as therapeutic agents |
EP01961468A EP1399172A1 (en) | 2000-08-16 | 2001-08-16 | Seal-oil-based pharmaceutical, cosmetic, dermo-cosmetic, hygiene, alimentary and para-alimentary (food-supplements) products; their methods of preparation; their uses as preventive and/or as therapeutic agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT102509 | 2000-08-16 | ||
PT102509A PT102509A (en) | 2000-08-16 | 2000-08-16 | PHARMACEUTICAL, COSMETIC AND DERMO-COSMETIC COMPOSITIONS, OF HYGIENE, FOOD AND FODDER, BASED ON FOCUS OIL, AND THEIR USE |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002013838A1 true WO2002013838A1 (en) | 2002-02-21 |
Family
ID=20085979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/PT2001/000020 WO2002013838A1 (en) | 2000-08-16 | 2001-08-16 | Seal-oil-based pharmaceutical, cosmetic, dermo-cosmetic, hygiene, alimentary and para-alimentary (food-supplements) products; their methods of preparation; their uses as preventive and/or as therapeutic agents |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1399172A1 (en) |
AU (1) | AU2001282730A1 (en) |
PT (1) | PT102509A (en) |
WO (1) | WO2002013838A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003055323A1 (en) * | 2001-12-27 | 2003-07-10 | Genesis Group Inc. | Seal oil based lipid emulsions and uses thereof |
WO2004075878A1 (en) * | 2003-02-26 | 2004-09-10 | Wei Liu | Fatty emulsion injection of seal oil, method for preparation and the use in manufacturing intravenous injection |
WO2006118463A1 (en) * | 2005-05-02 | 2006-11-09 | Olivita As | A combination of seal oil and cold-pressed virgin olive oil |
US7368144B2 (en) | 2000-08-11 | 2008-05-06 | Barry Callebaut France | Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof |
WO2008147562A2 (en) * | 2007-05-25 | 2008-12-04 | Childrens's Medical Center Corporation | Dietary formulations and methods for treatment of inflammation and other disorders |
US7666442B2 (en) * | 2004-08-31 | 2010-02-23 | Tracie Martyn International, Llc | Topical compositions comprising benfotiamine and pyridoxamine |
ITRM20090119A1 (en) * | 2009-03-19 | 2010-09-19 | Medivis S R L | OPHTHALMIC COMPOSITIONS OF OMEGA-3 AND OMEGA-6 POLYSATURATED FATTY ACIDS. |
ITMI20090521A1 (en) * | 2009-04-01 | 2010-10-02 | Salati Gian Luca Lamberto | COSMETIC COMPOSITION WITH MOISTURIZING ACTIVITY AND FAVORABLE SKIN ELECTICITY |
WO2012059158A1 (en) * | 2010-11-05 | 2012-05-10 | F. Holzer Gmbh | Composition and drug containing omega-3 fatty acids, and a modulator |
US9107430B2 (en) | 2008-01-22 | 2015-08-18 | Barry Callebaut Ag | Process for producing red or purple cocoa-derived material |
CN109771324A (en) * | 2019-03-29 | 2019-05-21 | 华熙生物科技股份有限公司 | A kind of eye skin care compositions of hirudin and hyaluronic acid substance |
CN112773887A (en) * | 2021-01-06 | 2021-05-11 | 温州医科大学 | Temperature-sensitive gel for colonic mucosa repair |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0296118A2 (en) * | 1987-06-16 | 1988-12-21 | Warner-Lambert Company | Oil compositions of increased viscosity and method of preparing same |
WO1996028150A1 (en) * | 1995-02-20 | 1996-09-19 | Marit Eriksen | Therapeutic skin cream |
WO2000044862A1 (en) * | 1999-01-29 | 2000-08-03 | Atlantis Marine Inc. | Process of converting rendered triglyceride oil from marine sources into bland, stable oil |
-
2000
- 2000-08-16 PT PT102509A patent/PT102509A/en not_active Application Discontinuation
-
2001
- 2001-08-16 WO PCT/PT2001/000020 patent/WO2002013838A1/en not_active Application Discontinuation
- 2001-08-16 AU AU2001282730A patent/AU2001282730A1/en not_active Abandoned
- 2001-08-16 EP EP01961468A patent/EP1399172A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0296118A2 (en) * | 1987-06-16 | 1988-12-21 | Warner-Lambert Company | Oil compositions of increased viscosity and method of preparing same |
WO1996028150A1 (en) * | 1995-02-20 | 1996-09-19 | Marit Eriksen | Therapeutic skin cream |
WO2000044862A1 (en) * | 1999-01-29 | 2000-08-03 | Atlantis Marine Inc. | Process of converting rendered triglyceride oil from marine sources into bland, stable oil |
Non-Patent Citations (1)
Title |
---|
B.DEUTCH E.A.: "N-3 PUFA from fish- or seal oil reduce atherogenic risk indicators in Danish women", NUTRITION RESEARCH, vol. 20, no. 8, 2000, pages 1065 - 1077, XP001041758 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7368144B2 (en) | 2000-08-11 | 2008-05-06 | Barry Callebaut France | Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof |
WO2003055323A1 (en) * | 2001-12-27 | 2003-07-10 | Genesis Group Inc. | Seal oil based lipid emulsions and uses thereof |
WO2004075878A1 (en) * | 2003-02-26 | 2004-09-10 | Wei Liu | Fatty emulsion injection of seal oil, method for preparation and the use in manufacturing intravenous injection |
US7666442B2 (en) * | 2004-08-31 | 2010-02-23 | Tracie Martyn International, Llc | Topical compositions comprising benfotiamine and pyridoxamine |
US20140134222A1 (en) * | 2004-08-31 | 2014-05-15 | Tracie Martyn International, Inc. | Topical benfotiamine and pyridoxamine compositions |
WO2006118463A1 (en) * | 2005-05-02 | 2006-11-09 | Olivita As | A combination of seal oil and cold-pressed virgin olive oil |
US8652508B2 (en) | 2007-05-25 | 2014-02-18 | Children's Medical Center Corporation | Dietary formulations and methods for treatment of inflammation and other disorders |
WO2008147562A2 (en) * | 2007-05-25 | 2008-12-04 | Childrens's Medical Center Corporation | Dietary formulations and methods for treatment of inflammation and other disorders |
WO2008147562A3 (en) * | 2007-05-25 | 2009-07-16 | Childrens S Medical Ct Corp | Dietary formulations and methods for treatment of inflammation and other disorders |
US8951550B2 (en) | 2007-05-25 | 2015-02-10 | Children's Medical Center Corporation | Dietary formulations and methods for treatment of inflammation and other disorders |
US9107430B2 (en) | 2008-01-22 | 2015-08-18 | Barry Callebaut Ag | Process for producing red or purple cocoa-derived material |
KR20110130431A (en) * | 2009-03-19 | 2011-12-05 | 티알비 케메디카 인터내셔널 에스.에이. | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids |
WO2010106571A3 (en) * | 2009-03-19 | 2010-11-18 | Medivis S.R.L. | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids |
US8957110B2 (en) | 2009-03-19 | 2015-02-17 | Trb Chemedica International S.A. | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids |
ITRM20090119A1 (en) * | 2009-03-19 | 2010-09-19 | Medivis S R L | OPHTHALMIC COMPOSITIONS OF OMEGA-3 AND OMEGA-6 POLYSATURATED FATTY ACIDS. |
KR101677308B1 (en) | 2009-03-19 | 2016-11-17 | 티알비 케메디카 인터내셔널 에스.에이. | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids |
ITMI20090521A1 (en) * | 2009-04-01 | 2010-10-02 | Salati Gian Luca Lamberto | COSMETIC COMPOSITION WITH MOISTURIZING ACTIVITY AND FAVORABLE SKIN ELECTICITY |
WO2012059158A1 (en) * | 2010-11-05 | 2012-05-10 | F. Holzer Gmbh | Composition and drug containing omega-3 fatty acids, and a modulator |
CN109771324A (en) * | 2019-03-29 | 2019-05-21 | 华熙生物科技股份有限公司 | A kind of eye skin care compositions of hirudin and hyaluronic acid substance |
CN109771324B (en) * | 2019-03-29 | 2021-12-10 | 华熙生物科技股份有限公司 | An eye skin care composition containing hirudin and hyaluronic acid |
CN112773887A (en) * | 2021-01-06 | 2021-05-11 | 温州医科大学 | Temperature-sensitive gel for colonic mucosa repair |
CN112773887B (en) * | 2021-01-06 | 2023-05-23 | 温州医科大学 | Temperature-sensitive gel for repairing colonic mucosa |
Also Published As
Publication number | Publication date |
---|---|
EP1399172A1 (en) | 2004-03-24 |
PT102509A (en) | 2002-02-28 |
AU2001282730A1 (en) | 2002-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5041664B2 (en) | Use of taurine to treat alopecia | |
CA2567189A1 (en) | Treatment for asthma and arthritis and other inflammatory diseases | |
CA2082418A1 (en) | Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof | |
ES2340510T3 (en) | USE OF RENTAL-FURANS FOR THE PREPARATION OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF OBESITY AND FOR THE COSMETIC TREATMENT OF THE EXCEESS OF WEIGHT. | |
MX2007001098A (en) | Emu oil and fruit composition. | |
WO2002013838A1 (en) | Seal-oil-based pharmaceutical, cosmetic, dermo-cosmetic, hygiene, alimentary and para-alimentary (food-supplements) products; their methods of preparation; their uses as preventive and/or as therapeutic agents | |
ES2364153T3 (en) | USE OF RENT-FURANS FOR THE COSMETIC TREATMENT OF CELLULITE. | |
EP3439676B1 (en) | Fish oil topical composition | |
WO2019046735A1 (en) | Health promoting composition and methods of use supplement related applications | |
KR20110127447A (en) | Compositions for preventing hair loss or accelerating the growth of hair | |
KR20000046633A (en) | Composition for treatment of atopic dermatonosis | |
JP2002212087A (en) | Skin care preparation | |
JP4583655B2 (en) | Anti-allergic skin external composition | |
JP2004229534A (en) | Hydrolyzed eggshell membrane-containing drink | |
KR101874830B1 (en) | Antibacterial Cosmetics Composition | |
JPH10120579A (en) | Skin preparation for improving sputum for external use | |
KR20170116334A (en) | A cosmetic composition for manufacturing by the using of propolis, and the cosmetic manufactured by the composition | |
CN101297705B (en) | Compound Tibet sheep placenta capsule for removing wrinkle and resisting aging | |
JPH10175868A (en) | Water (of chinese medicine idea) improving composition | |
KR20000069310A (en) | Extracellular matrix production promoter | |
US20120308586A1 (en) | Composition based on extra virgin olive oils | |
JP2003335688A (en) | Bradykinin receptor antagonist | |
JPS63277604A (en) | Alpha-linolenic acid-containing cosmetic | |
JP2002527472A (en) | Indigestion treatment | |
JPH07278001A (en) | External preparation for skin and bathing agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001961468 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001961468 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001961468 Country of ref document: EP |